Across TCGA pan-cancer cohorts, SMC4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SMC4 data layer compared with 28 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SMC4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SMC4 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.
LSCC, LUAD, and CCRCC are the cancer types where SMC4 mass-spec protein most reproducibly stratifies survival.